THE CURRENCY OF LIFE.
Another decade with a spouse. A few more years with your best friend. A rich, full life rather than one cut short.
How do we place value on these?
Thanks to a system that has long encouraged entrepreneurial investment in research, breakthroughs in biopharmaceutical medicines are delivering more than stunning outcomes. More than even cures. They are giving us more time.
Time. What is more precious? What is more priceless? And what a wonderful reason to push forward to the future cures and treatments we see so close at hand.
TODAY, THANKS TO BREAKTHROUGHS IN BIOTECHNOLOGY, WE ARE DELIVERING TREATMENTS AND CURES TO OUR MOST DEADLY, AND COSTLY, DISEASES.
As America’s biopharmaceutical researchers and entrepreneurs, we envision a future where new cures and therapies radically transform the way we treat patients for cancer, HIV/AIDS, Alzheimer’s and scores of other deadly diseases that plague our world. So that we can accelerate the advances that promise to benefit us all, we believe it is important to share and celebrate these exciting innovations. Read more
NOTHING HAS THE POWER TO CURB HEALTH CARE COSTS QUITE LIKE A CURE.
Breakthroughs in biotechnology are doing more than saving lives. They are saving on costs.
Biotechnology innovations often result in fewer hospital stays, fewer surgeries, fewer doctors’ visits and, ultimately, reduce health care costs. Read more
INNOVATIONS IN BIOTECHNOLOGY WILL DELIVER A MORE SUSTAINABLE HEALTH CARE MODEL.
The U.S. leads the world in biotechnology innovation. Why? Because our private sector system of incentivizing innovation is working.
By continuing to fund the innovation pipeline that has served us so well, we will be able to reduce the costs associated with modern-day health care. Ultimately, these innovations will reduce the health care burden carried by America’s taxpayers, deliver a more sustainable health care model for future generations and fuel an economic engine capable of helping power the U.S. economy into the 21st Century. Read more
90% OF BIOPHARMA COMPANIES DO NOT EARN A PROFIT.
Media coverage focusing on the cost of prescription medicines creates an impression of biopharmaceutical companies as enterprises that put profit above all else. The reality could not be more different.
Enormous amounts of capital and time are required to bring a drug through the development and approval process. Of the approximately 1,200 biopharma companies in the United States, more than 90 percent do not earn a profit. And 70 percent of the industry’s clinical pipeline is attributed to small companies. Read more
THE RISKS ARE GREAT.
BUT THE REWARDS ARE GREATER.
As the Economist Magazine noted, “Creating new drugs through biotechnology is at the risky end of a business in which superhuman stamina and bottomless pockets are minimum requirements.” Nonetheless, scientists and entrepreneurs continue to push forward every day, despite the long odds and frequent setbacks, because they know what is at stake: the child who can live a rich, full life, the proud father who gets to walk his daughter down the aisle and the couple able to build many more years of memories. Read more
MAKE NO MISTAKE. THE PACE OF INNOVATION WILL AFFECT YOUR FAMILY. YOUR FRIENDS. YOU.
The reality is that, in the course of our lives, we are all likely to encounter situations where our loved ones will be positively impacted by advances in biopharmaceutical medicines.
Those critical of the ecosystem that incentivizes risk-taking entrepreneurs to innovate have missed an important point: The current system benefits us all, and it’s working….for our families, our loved ones and our society. Let’s continue to build on that work for future generations. Read more